Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 1.00 |
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.73 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.53 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.52 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1449310 | 0.95 | HRH3 (1.00) | HRH3L3MBTL3L3MBTL1MBTD1KDM4E | |
| SCHEMBL522796 | 0.89 | HRH3 (1.00) | HRH3L3MBTL3L3MBTL1MBTD1HPGD | |
| Citric Acid SCHEMBL1449898 | 0.89 | HRH3 (0.78) | HRH3L3MBTL3L3MBTL1MBTD1KDM4E | |
| Hydrochloric Acid SCHEMBL1450634 | 0.88 | HRH3 (0.98) | HRH3L3MBTL3L3MBTL1MBTD1HPGD | |
| SCHEMBL1177463 | 0.87 | HRH3 (0.77) | HRH3L3MBTL3L3MBTL1MBTD1KDM4E | |
| SCHEMBL1449894 | 0.86 | HRH3 (0.76) | HRH3L3MBTL3L3MBTL1MBTD1KDM4E | |
| SCHEMBL23718118 | 0.84 | L3MBTL3 (1.00) | HRH3L3MBTL3L3MBTL1MBTD1KDM4E | |
| Citric Acid SCHEMBL1449891 | 0.84 | HRH3 (0.78) | HRH3L3MBTL3L3MBTL1MBTD1KDM4E | |
| Bavisant SCHEMBL522603 | 0.84 | HRH3 (1.00) | HRH3L3MBTL3L3MBTL1MBTD1HPGD | |
| Bavisant SCHEMBL521755 | 0.82 | HRH3 (1.00) | HRH3L3MBTL3L3MBTL1MBTD1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101321730-B | Cyclopropylamines as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV | 2012-11-14 | — | — | CN | disclosed |
| US-8026242-B2 | Cyclopropyl amines as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-27 | — | — | US | disclosed |
| US-8026242-B2 | Cyclopropyl amines as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-27 | — | — | US | disclosed |
| US-8026242-B2 | Cyclopropyl amines as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-27 | — | — | US | disclosed |
| US-20110136797-A1 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-09 | — | — | US | disclosed |
| US-20110136797-A1 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-09 | — | — | US | disclosed |
| US-20110136797-A1 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-09 | — | — | US | disclosed |
| US-7910582-B2 | Cyclopropyl amines as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-22 | — | — | US | disclosed |
| US-7910582-B2 | Cyclopropyl amines as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-22 | — | — | US | disclosed |
| US-7910582-B2 | Cyclopropyl amines as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-22 | — | — | US | disclosed |
| EP-1948607-B1 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-04-07 | — | — | EP | disclosed |
| US-7687499-B2 | Cyclopropyl amines as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-30 | — | — | US | disclosed |
| US-7687499-B2 | Cyclopropyl amines as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-30 | — | — | US | disclosed |
| US-7687499-B2 | Cyclopropyl amines as modulators of the histamine H3 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-30 | — | — | US | disclosed |
| EP-1948607-A2 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007035425-A2 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007035425-A2 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-29 | — | — | WO | disclosed |
| US-20070066821-A1 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066821-A1 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066821-A1 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066821-A1 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH2 | HRH3 1/4885L3MBTL3 3455/4885L3MBTL1 3151/4885 |
| US-20110136797-A1 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH2 | HRH3 1/4885L3MBTL3 3455/4885L3MBTL1 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.